Skip to main content

Advertisement

SpringerLink
Log in

Future therapies for inflammatory bowel disease

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Three domains are accepted components of the etiology of inflammatory bowel disease (IBD): genetic predisposition, environmental stimuli, and abnormal immune response. The latter two are reasonable targets for medical therapies in the near future, whereas all three merit consideration for the more distant future as techniques of genetic manipulation evolve. In this review we summarize some of the fundamental concepts and offer comments on treatments for IBD that are likely and desirable in the near and distant future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pizarro TT, Arseneau KO, Cominelli F: Lessons from genetically engineered animal models XI. Novel mouse models to study pathogenic mechanisms of Crohn’s disease. Am J Physiol Gastrointest Liver Physiol 2000, 278:G665–6699. This paper reviews genetically manipulated models of intestinal inflammation and characterizes two novel mouse models of enteritis that express a Crohn’s disease-like phenotype, namely the TNF DeltaARE model of TNF overexpression and the SAMP1/Yit model of spontaneous ileitis. These models offer a powerful tool to investigate potential causes of human disease and may allow the development of novel disease-modifying therapeutic modalities for the treatment of Crohn’s disease.

    PubMed  CAS  Google Scholar 

  2. Rutgeerts P, Geboes K, Peeters M, et al.: Effect of fecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet 1991, 338:771–774.

    Article  PubMed  CAS  Google Scholar 

  3. D’Haens G, Geboes K, Peeters M, et al.: Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998, 114:262–267.

    Article  PubMed  CAS  Google Scholar 

  4. Fasoli R, Kettlewell MG, Mortensen N, Jewell DP: Response to faecal challenge in defunctioned colonic Crohn’s disease: prediction of long-term course. Br J Surg 1990, 77:616–617.

    Article  PubMed  CAS  Google Scholar 

  5. Hiwatashi N: Enteral nutrition for Crohn’s disease in Japan. Dis Colon Rectum 1997, 40:S48-S53.

    Article  PubMed  CAS  Google Scholar 

  6. Belluzzi A, Brignola C, Campieri M, et al.: Effect of an entericcoated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med 1996, 334:1557–1560.

    Article  PubMed  CAS  Google Scholar 

  7. Sartor RB: The influence of normal microbial flora on the development of chronic mucosal inflammation. Res Immunol 1997, 148:567–576.

    Article  PubMed  CAS  Google Scholar 

  8. Swidsinski A, Ladhoff A, Pernthaler A, et al.: Mucosal flora in inflammatory bowel disease. Gastroenterology 2002, 122:44–54.

    Article  PubMed  Google Scholar 

  9. Guarner F, Schaafsma GJ: Probiotics. Int J Food Microbiol 1998, 39:237–238.

    Article  PubMed  CAS  Google Scholar 

  10. Madsen K, Cornish A, Soper P, et al.: Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001, 121:580–591.

    Article  PubMed  CAS  Google Scholar 

  11. Neish AS, Gewirtz AT, Zeng H, et al.: Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 2000, 289:1560–1563.

    Article  PubMed  CAS  Google Scholar 

  12. Rembacken BJ, Snelling AM, Hawkey PM, et al.: Non-pathogenic Escherichia coli versus mesalamine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999, 354:635–639.

    Article  PubMed  CAS  Google Scholar 

  13. Kruis W, Schutz E, Fric P, et al.: Double-blind comparison of an oral Escherichia coli preparation and mesalamine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997, 11:853–858.

    Article  PubMed  CAS  Google Scholar 

  14. Wallet F, Dessein R, Armand S, Courcol RJ: Molecular diagnosis of endocarditis due to Lactobacillus casei subsp. rhamnosus. Clin Infect Dis. 2002, 35:117–119.

    Article  Google Scholar 

  15. Lherm T, Monet C, Nougiere B, et al.: Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002, 28:797–801.

    Article  PubMed  Google Scholar 

  16. Venturi A, Gionchetti P, Rizzello F, et al.: Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999, 13:1103–1108.

    Article  PubMed  CAS  Google Scholar 

  17. Gionchetti P, Rizzello F, Venturi A, et al.: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305–309.

    Article  PubMed  CAS  Google Scholar 

  18. Gionchetti P, Rizzello F, Helwig U, et al.: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebocontrolled trial. Gastroenterology 2003, 124:1202–1209.

    Article  PubMed  Google Scholar 

  19. Guslandi M, Mezzi G, Sorghi M, Testoni PA: Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 2000, 45:1462–1464.

    Article  PubMed  CAS  Google Scholar 

  20. Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003, 348:601–608.

    Article  PubMed  CAS  Google Scholar 

  21. Targan SR, Hanauer SB, van Deventer SJH, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med 1997, 337:1029–1035.

    Article  PubMed  CAS  Google Scholar 

  22. Hanaeur SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet 2002, 359:1541–1549.

    Article  Google Scholar 

  23. Present DH, Rutgeerts P, Targan S, et al.: Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999, 340:1398–1405.

    Article  PubMed  CAS  Google Scholar 

  24. Sands B, van Deventer S, Bernstein C, et al.: Long-term treatment of fistulizing Crohn’s disease: response to infliximab in the ACCENT II trial through 54 weeks [abstract]. Gastroenterology 2002, 122:A81.

    Google Scholar 

  25. Sandborn WJ, Targan SR: Biologic therapy of inflammatory bowel diseases. Gastroenterology 2002, 122:1592–1608. This review is densely packed with detailed information about successful biologic agents and gives a useful survey of others.

    Article  PubMed  CAS  Google Scholar 

  26. Lugering A, Schmidt M, Lugering N, et al.: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology 2001, 121:1145–1157.

    Article  PubMed  CAS  Google Scholar 

  27. Marini M, Bamias G, Rivera-Nieves J, et al.: TNF-alpha neutralization ameliorates the severity of murine Crohn’s-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc Natl Acad Sci U S A 2003, 100:8366–8371.

    Article  PubMed  CAS  Google Scholar 

  28. Neurath MF, Fuss I, Kelsall BL, et al.: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995, 182:1281–1290.

    Article  PubMed  CAS  Google Scholar 

  29. Salmi M, Alanen K, Grenman S, et al.: Immune cell trafficking in utero and during early life is dominated by the mucosal addressin MAdCAM-1 in humans. Gastroenterology 2001, 121:853–864.

    Article  PubMed  CAS  Google Scholar 

  30. Ghosh S, Goldin E, Gordon FH, et al.: Natalizumab for active Crohn’s disease. N Engl J Med 2003, 348:24–32.

    Article  PubMed  CAS  Google Scholar 

  31. Pizarro TT, Michie MH, Bentz M, et al.: IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn’s disease: expression and localization in intestinal mucosal cells. J Immunol 1999, 162: 6829–6835.

    PubMed  CAS  Google Scholar 

  32. Cordoba-Rodriguez R, Frucht DM: IL-23 and IL-27: new members of the growing family of IL-12-related cytokines with important implications for therapeutics. Expert Opin Biol Ther. 2003, 3:715–723.

    Article  PubMed  CAS  Google Scholar 

  33. Elson CO, Beagley KW, Sharmanov AT, et al.: Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J Immunol 1996, 157:2174–2185.

    PubMed  CAS  Google Scholar 

  34. Bar-Meir S, Chowers Y, Lavy A, et al.: Budesonide versus prednisone in the treatment of active Crohn’s disease: the Israeli Budesonide Study Group. Gastroenterology 1998, 115:835–840.

    Article  PubMed  CAS  Google Scholar 

  35. Bickston SJ, Cominelli F: Recombinant interleukin 10 for the treatment of active Crohn’s disease: lessons in biologic therapy. Gastroenterology 2000, 119:1781–1783.

    Article  PubMed  CAS  Google Scholar 

  36. Sinha A, Nightingale J, West KP, et al.: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate leftsided ulcerative colitis or proctitis. N Engl J Med 2003, 349:350 -357.

    Article  PubMed  CAS  Google Scholar 

  37. Iyer S, Lahana R, Buelow R: Rational design and development of RDP58. Curr Pharm Des 2002, 8:2217–2229.

    Article  PubMed  CAS  Google Scholar 

  38. Steidler L, Hans W, Schotte L, et al.: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000, 289:1352–1355.

    Article  PubMed  CAS  Google Scholar 

  39. Nakase H, Okazaki K, Tabata Y, Chiba T: Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease. J Gastroenterol 2003, 38:59–62.

    PubMed  Google Scholar 

  40. Lamprecht A, Ubrich N, Yamamoto H, et al.: Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2001, 299:775–781.

    PubMed  CAS  Google Scholar 

  41. Bonen DK, Cho JH: The genetics of inflammatory bowel disease. Gastroenterology 2003, 124:521–536. Recent update on data supporting genetic susceptibility to inflammatory bowel disease and explanation of current candidate loci.

    Article  PubMed  CAS  Google Scholar 

  42. Binder V: Genetic epidemiology in inflammatory bowel disease. Dig Dis 1998, 16:351–355.

    Article  PubMed  CAS  Google Scholar 

  43. Sands BE: Crohn’s disease. In Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Edited by Feldman M, Friedman LS, Sleisenger MH. Philadelphia: WB Saunders; 2002:2005–2038.

    Google Scholar 

  44. Hendrickson BA, Gokhale R, Cho JH: Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002, 15:79–94.

    Article  PubMed  Google Scholar 

  45. Kyo K, Parkes M, Takei Y, et al.: Association of ulcerative colitis with rare VNTR alleles of the human intestinal mucin gene, MUC3. Hum Mol Genet 1999, 8:307–311.

    Article  PubMed  CAS  Google Scholar 

  46. Katayama K, Wada K, Nakajima A, et al.: A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 2003, 124:1538–1542.

    Article  Google Scholar 

  47. Sasaki M, Jordan P, Houghton J, et al.: Transfection of IL-10 expression vectors into endothelial cultures attenuates alpha4beta7-dependent lymphocyte adhesion mediated by MAdCAM-1. BMC Gastroenterology 2003, 3:3.

    Article  PubMed  Google Scholar 

  48. Macdonald TT: Viral vectors expressing imunoregulatory cytokines to treat inflammatory bowel disease. Gut 1998, 42:460–461.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Virginia Digestive Health Center of Excellence (UVA-DHCOE), MSB-2nd floor, Room 2121, 22908-0708, Charlottesville, VA, USA

    Stephen J. Bickston MD, Lawrence W. Comerford MD & Fabio Cominelli MD, PhD

Authors
  1. Stephen J. Bickston MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lawrence W. Comerford MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fabio Cominelli MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bickston, S.J., Comerford, L.W. & Cominelli, F. Future therapies for inflammatory bowel disease. Curr Gastroenterol Rep 5, 518–523 (2003). https://doi.org/10.1007/s11894-003-0043-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-003-0043-5

Keywords

Search

Navigation